secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0000950170-24-140955
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment
--------------------------------------------------------------------------------

- FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.
- Clearance triggers $13M cash earnout payment to Physio-Assist sellers under July 2023 purchase agreement.
- Device targets mucus hypersecretion in Bronchiectasis, COPD, Cystic Fibrosis, and Primary Ciliary Dyskinesia.
- Inogen plans limited U.S. launch in 2025 via existing HCP, B2B, and direct-to-patient channels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024140955/0000950170-24-140955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024140955/ingn-20241230.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-140955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer